Canada markets closed

OSE Immunotherapeutics SA (0RAD.L)

LSE - LSE Delayed Price. Currency in EUR
Add to watchlist
6.71-0.02 (-0.30%)
At close: 11:01AM BST
Currency in EUR

Valuation Measures4

Market Cap (intraday) N/A
Enterprise Value N/A
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm)N/A
Price/Book (mrq)N/A
Enterprise Value/Revenue N/A
Enterprise Value/EBITDA N/A

Trading Information

Stock Price History

Beta (5Y Monthly) 0.75
52-Week Change 3-3.23%
S&P500 52-Week Change 326.27%
52 Week High 37.31
52 Week Low 32.73
50-Day Moving Average 34.19
200-Day Moving Average 34.18

Share Statistics

Avg Vol (3 month) 32.67k
Avg Vol (10 day) 32.08k
Shares Outstanding 514.61M
Implied Shares Outstanding 6N/A
Float 814.6M
% Held by Insiders 127.66%
% Held by Institutions 12.13%
Shares Short 4N/A
Short Ratio 4N/A
Short % of Float 4N/A
Short % of Shares Outstanding 4N/A
Shares Short (prior month ) 4N/A

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 30.00
Trailing Annual Dividend Yield 30.00%
5 Year Average Dividend Yield 4N/A
Payout Ratio 4N/A
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2023
Most Recent Quarter (mrq)Dec 31, 2023

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-1,091.02%

Management Effectiveness

Return on Assets (ttm)-16.53%
Return on Equity (ttm)-82.70%

Income Statement

Revenue (ttm)2.23M
Revenue Per Share (ttm)0.11
Quarterly Revenue Growth (yoy)-61.50%
Gross Profit (ttm)N/A
EBITDA -20.41M
Net Income Avi to Common (ttm)-23M
Diluted EPS (ttm)-0.93
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)18.67M
Total Cash Per Share (mrq)0.91
Total Debt (mrq)45.8M
Total Debt/Equity (mrq)199.35%
Current Ratio (mrq)1.62
Book Value Per Share (mrq)1.12

Cash Flow Statement

Operating Cash Flow (ttm)-19.76M
Levered Free Cash Flow (ttm)-11.42M